Stroke
Drug research and approvals for stroke: what is recruiting, what Health Canada authorized, FDA orphan designations and EU medicines. See every condition.
As of Nov 18, 2026, 1,698 studies of stroke are recruiting on ClinicalTrials.gov, Health Canada has authorized 49 drug trials for it since 2013, FDA has 0 approved and 8 open orphan designations naming it, and the EU has 17 authorised medicines for it.
- Recruiting worldwide: 1,698
- Trials authorized in Canada: 49
- FDA orphan approvals: 0
- EU medicines: 17
Recruiting Now
Newest start dates first, of 1,698 recruiting on ClinicalTrials.gov ↗- Exercise Induced Hypoalgesia in Pain-free Stroke and Healthy Populations: a Cohort StudyNCT07327593 · Not applicable · Neuron, Spain · starts Apr 1, 2027
- Application of Digital Twins' Technology in Patients Who Had a Stroke, With Moyamoya Disease and With Cerebral Amyloid…NCT06714097 · Not applicable · Fondazione I.R.C.C.S. Istituto Neurologico Carlo Besta · starts Jan 1, 2027
- Interfacing With NeuroTechnology to Expand Neural Throughput (INTENT)NCT07521930 · Not applicable · Johns Hopkins University · starts Jan 1, 2027
- Evaluation of the Predictive Value of Microemboli Detected by Robotic Transcranial Doppler (TCD) for the Occurrence of…NCT07932080 · Not applicable · CHC Montlegia · starts Dec 1, 2026
- A Novel Multimodal Approach to Promote Motor Recovery and Plasticity After StrokeNCT07887880 · Not applicable · University of Utah · starts Nov 11, 2026
- Optimal Targeted High-definition Transcranial Direct Current Stimulation for Reducing Post-stroke Upper Limb Motor…NCT07599774 · Not applicable · Carle Foundation Hospital · starts Nov 9, 2026
- Continuous Blood Pressure Variability and Small Vessel Disease in Acute Ischemic StrokeNCT07903922 · Not reported · Minyoul Baik · starts Nov 6, 2026
- Feasibility Of Sleep Treatment Education in Stroke Rehabilitation SettingsNCT07934485 · Not applicable · University of Oxford · starts Nov 3, 2026
- Short-Term External Trigeminal Nerve Stimulation for Acute Ischemic StrokeNCT07911605 · Not applicable · Xidian University · starts Nov 3, 2026
- Experimental PBT Study in Fall-prone SubjectsNCT07654335 · Not applicable · University Rehabilitation Institute, Republic of Slovenia · starts Nov 2, 2026
Drug Pipeline
37 approved, 47 in phase 3, 56 in phase 2, 16 in phase 1 or earlier; from ChEMBL's drug indications, furthest stage reached for this conditionApproved: Alteplase, Aspirin, Warfarin, Clopidogrel, Apixaban, Rivaroxaban, Ticagrelor, Edoxaban, Dipyridamole, Atorvastatin, Simvastatin, Candesartan cilexetil, Lisinopril anhydrous, Propranolol, Telmisartan, Valsartan, Dabigatran etexilate, Nebivolol, Aliskiren, Atenolol, Azilsartan medoxomil, Benazepril, Celecoxib, Dantrolene, Losartan, Metoprolol, Nadolol, Olmesartan medoxomil, Quinapril, Ramipril, Vorapaxar, Ticlopidine, Torsemide, Sitagliptin, Eplerenone, Amlodipine, Evolocumab
- Tenecteplase
- Phase 3 Tissue-type plasminogen activator exogenous protein
- Onabotulinumtoxina
- Phase 3 Synaptosomal nerve-associated protein 25 (SNAP-25) inhibitor
- Abciximab
- Phase 3 Integrin alpha-IIb/beta-3 inhibitor
- Desmoteplase
- Phase 3 Plasminogen activator
- Fluoxetine
- Phase 3 Serotonin transporter inhibitor
- Levodopa
- Phase 3 Dopamine D3 receptor agonist
- Urokinase
- Phase 3 Urokinase-type plasminogen activator exogenous protein
- Carbidopa anhydrous
- Phase 3 DOPA decarboxylase inhibitor
- Rosuvastatin
- Phase 3 HMG-CoA reductase inhibitor
- Dabigatran
- Phase 3 Thrombin inhibitor
- Nerinetide
- Phase 3
- Citalopram
- Phase 3 Serotonin transporter inhibitor
- Hydroxyurea
- Phase 3 Ribonucleoside-diphosphate reductase RR1 inhibitor
- Nitroglycerin
- Phase 3 Soluble guanylate cyclase activator
- Lidocaine
- Phase 3 Sodium channel alpha subunit blocker
- Heparin
- Phase 3 Antithrombin-III activator
- Donepezil
- Phase 3 Acetylcholinesterase inhibitor
- Incobotulinumtoxina
- Phase 3 Synaptosomal nerve-associated protein 25 (SNAP-25) inhibitor
- Lithium carbonate
- Phase 3 Inositol-1(or 4)-monophosphatase 1 inhibitor
- Norepinephrine
- Phase 3 Adrenergic receptor agonist
- Remifentanil
- Phase 3 Mu opioid receptor agonist
- Dalteparin sodium
- Phase 3 Antithrombin-III activator
- Estrogens, conjugated
- Phase 3 Estrogen receptor agonist
- Suxamethonium
- Phase 3 Muscle-type nicotinic acetylcholine receptor agonist
- Imatinib
- Phase 3 Tyrosine-protein kinase ABL inhibitor
- Modafinil
- Phase 3 Dopamine transporter inhibitor
- Phenylephrine
- Phase 3 Adrenergic receptor alpha-1 agonist
- Clevidipine
- Phase 3 Voltage-gated L-type calcium channel blocker
- Propofol
- Phase 3 GABA-A receptor; anion channel positive allosteric modulator
- Etomidate
- Phase 3 GABA-A receptor; anion channel positive modulator
Showing the 30 furthest along of 119 in trials.
How Its Trials Ended
6,163 ClinicalTrials.gov studies of the condition, classified by TrialPanorama, partly automatically, so some labels are wrongOf the 976 whose ending is known, 42% met their primary endpoint, 11% missed it and 47% stopped early.
- Completed, result not reported2,51641%
- Ongoing1,63827%
- Status unknown1,03317%
- Met its primary endpoint4137%
- Stopped: other or unclear2825%
- Missed its primary endpoint1052%
- Stopped: enrollment or feasibility1002%
- Stopped: lack of efficacy270%
- Stopped: funding240%
- Stopped: sponsor or business decision190%
- Stopped: safety60%
Trials Authorized in Canada
The 10 newest of 49; search them all in Canada trials| Sep 25, 2026 | A phase 2a multicenter, randomized, double-blind, placebo-controlled, parallel-arm domain within the act-global trial platform, to evaluate the dose-response,…NTS-521 | Neurotrauma Sciences, LLC | Ongoing |
| Sep 10, 2026 | A phase 3, randomized, multicenter, double-blind study to assess stroke and systemic embolism prevention with regn7508, a monoclonal antibody against factor…REGN7508 / eliquis | Regeneron | Ongoing |
| Jul 10, 2026 | Safety and efficacy of intravenous thrombolysis in patients with ischemic stroke on treatment with direct oral anticoagulants: do-it – the doac intravenous…Tnkase / activase | Insel Gruppe AG, Inselspital (University Hospital) Bern | Pending |
| Nov 6, 2025 | Glucagon-like peptide-1 receptor agonists for endovascular stroke thrombectomyOzempic / apo-semaglutide injection | Hamilton Health Sciences Corporation | Pending |
| Jan 24, 2025 | Optimizing reperfusion to improve outcomes and neurologic function (orion): a multicenter, double-blind, placebo controlled, randomized, parallel-group, phase…JX10 | Corxel Pharmaceuticals, Co, Ltd | Ongoing |
| Nov 1, 2024 | Phase 2/3 adaptive design, randomized double-blind placebo-controlled study to evaluate the safety and efficacy of dm199 for the treatment of acute ischemic…DM199 (rinvecalinase alfa) | Diamedica Inc | Ongoing |
| Oct 1, 2024 | A multicenter, double-blinded, placebo-controlled, single ascending dose, twopart, randomized, phase 2 clinical trial to assess safety, tolerability,…BB-031 | Basking Biosciences, Inc | Ongoing |
| Aug 15, 2024 | An investigator-initiated phase 3 multicentre open-label blinded-endpoint randomized controlled trial to evaluate the efficacy and safety of very low-dose…Edoxaban | Sunnybrook Research Institute | Pending |
| May 14, 2024 | Nuance-icad: effect of genotype-guided oral p2y12 inhibitor selection vs conventional clopidogrel therapy in symptomatic intracranial atherosclerotic disease:…Ticagrelor | Sunnybrook Research Institute | Ongoing |
| Mar 7, 2024 | Thrombolysis domain (act when) a multi-factorial, multi-arm, multi-stage, randomised, global adaptive platform trial for stroke (act-global)Tnkase | Governors Of The University Of Calgary/Dr. Bijoy Menon | Ongoing |
FDA Orphan Designations
Approved first, then open designations, newest first| Aug 27, 2026 | TaurineTreatment of mitochondrial encephalomyopathy, lactic acidosis, and stroke-like episodes (MELAS) | Kalevala Therapeutics, Inc. | Designated |
| Oct 14, 2024 | GlyburideTreatment of large territory acute ischemic stroke | Remedy Pharmaceuticals, Inc. | Designated |
| Apr 22, 2019 | MelatoninTreatment of heat stroke | WORPHMED Srl | Designated |
| Jan 25, 2017 | Nicotinamide ribosideTreatment of mitochondrial encephalopathy, lactic acidosis, and stroke-like episodes syndrome (MELAS) | Rejuvenation Therapeutics | Designated |
| Jan 12, 2017 | GlyburideTreatment of severe cerebral edema in patients with acute ischemic stroke | Remedy Pharmaceuticals, Inc. | Designated |
| Apr 11, 2014 | H-Tyr-Gly-Arg-Lys-Lys-Arg-Arg-Gln-Arg-Arg-Arg-Lys-Leu-Ser-Se…Treatment of acute ischemic stroke patients presenting within 3 hours of symptom onset | NoNO, Inc. | Designated |
| Sep 25, 2012 | Dantrolene sodiumTreatment of heat stroke | Eagle Pharmaceuticals, Inc. | Designated |
| Apr 18, 2011 | Tissue Plasminogen activatorTreatment of acute ischemic stroke (AIS) in children age 16 years and younger. | Catherine Amlie-Lefond, MD | Designated |
Medicines Authorised in the EU
Newest first; 15 of 17| Jul 23, 2020 | Apixaban AccordApixaban · generic | Accord Healthcare S.L.U. | EMA ↗ |
| Apr 19, 2017 | RoteasEdoxaban | Berlin-Chemie AG | EMA ↗ |
| Jun 19, 2015 | LixianaEdoxaban | Daiichi Sankyo Europe GmbH | EMA ↗ |
| Feb 18, 2015 | Clopidogrel ratiopharmClopidogrel · generic | Teva B.V. | EMA ↗ |
| Oct 28, 2010 | Clopidogrel HCSClopidogrel · generic | HCS bvba | EMA ↗ |
| Oct 16, 2009 | Clopidogrel Viatris (previously Clopidogrel Taw Pharma)Clopidogrel · generic | Viatris Limited | EMA ↗ |
| Sep 28, 2009 | ZylltClopidogrel · generic | KRKA tovarna zdravil d.d. Novo mesto | EMA ↗ |
| Sep 23, 2009 | Clopidogrel KrkaClopidogrel · generic | KRKA tovarna zdravil d.d. Novo mesto | EMA ↗ |
| Sep 23, 2009 | Clopidogrel TADClopidogrel · generic | Tad Pharma GmbH | EMA ↗ |
| Sep 21, 2009 | Clopidogrel Taw Pharma (previously Clopidogrel Mylan)Clopidogrel · generic | Taw Pharma (Ireland) Limited | EMA ↗ |
| Sep 21, 2009 | Clopidogrel BGR (previously Zylagren)Clopidogrel · generic | Biogaran | EMA ↗ |
| Sep 20, 2009 | Clopidogrel Krka d.d. (previously Zopya)Clopidogrel · generic | Norpharm Regulatory Services Ltd | EMA ↗ |
| Jul 27, 2009 | GrepidClopidogrel · generic | Pharmathen S.A. | EMA ↗ |
| Jul 27, 2009 | Clopidogrel Teva (hydrogen sulphate)Clopidogrel · generic | Teva Pharma B.V. | EMA ↗ |
| Jul 15, 2008 | Clopidogrel Zentiva (previously Clopidogrel Winthrop)Clopidogrel | Zentiva k.s. | EMA ↗ |
Condition names come from Health Canada's trial database. Orphan designations and EU medicines are matched when their indication names the condition as whole words, so a broader or differently worded indication can be missed. Recruiting counts are live from ClinicalTrials.gov's own condition search, refreshed daily. ClinicalTrials.gov, Health Canada Clinical Trials Database, FDA orphan designations, EMA